Predictors of mortality in COPD

Respiratory Medicine

Volumn 104, Issue 6, 2010, Pages 773-779

  Celli, Bartolome R ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Biomarkers; BODE; COPD; FEV1

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; PLACEBO; BIOLOGICAL MARKER;

AEROBIC CAPACITY; AEROBIC EXERCISE; BODY MASS; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; DYSPNEA; EXHALATION; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG RESECTION; MORTALITY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; SURVIVAL TIME; TOTAL LUNG CAPACITY; TREATMENT RESPONSE; WALKING; EXERCISE TOLERANCE; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PHYSIOLOGY;

BIOLOGICAL MARKERS; BODY MASS INDEX; DYSPNEA; EXERCISE TOLERANCE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 77952290394     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.12.017     Document Type: Review

References (42)

1. Global burden of disease 2004 update: part 2, causes of death (2008), World Health Organization. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part2.pdf Available from:
2. Murray C.J., and Lopez A.D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349 9063 (1997 May 17) 1436-1442
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Updated 2007; January 2008. Available from: http://www.goldcopd.org/GuidelinesResources.asp?l1=2&l2=0.
4. Celli B.R., MacNee W., Agusti A., et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 6 (2004) 932-946
5. National Heart Lung and Blood Institute. Morbidity and mortality: 2007 chartbook on cardiovascular, lung, and blood diseases (June 2007), US Department of Health and Human Services, Bethesda, MD. Available from: www.nhlbi.nih.gov/resources/docs/cht-book.htm [cited 2008 March 31]
6. Barnes P.J., and Hansel T.T. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364 9438 (2004 Sep 11-17) 985-996
7. Barnes P.J. COPD: is there light at the end of the tunnel?. Curr Opin Pharmacol 4 3 (2004 Jun) 263-272
8. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364 9435 (2004 Aug 21-27) 709-721
9. Fletcher C., and Peto R. The natural history of chronic airflow obstruction. Br Med J 1 6077 (1977 Jun 25) 1645-1648
10. Bang K.M., Gergen P.J., Kramer R., and Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 103 2 (1993 Feb) 536-540
11. Beaty T.H., Cohen B.H., Newill C.A., Menkes H.A., Diamond E.L., and Chen C.J. Impaired pulmonary function as a risk factor for mortality. Am J Epidemiol 116 1 (1982 Jul) 102-113
12. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., and Hawthorne V.M. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Bmj 313 7059 (1996 Sep 21) 711-715 discussion 5-6
13. Schunemann H.J., Dorn J., Grant B.J., Winkelstein Jr. W., and Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo health study. Chest 118 3 (2000 Sep) 656-664
14. Barnes P.J., and Celli B. Systemic manifestations and comorbidities of COPD. Eur Respir J 33 (2009) 1165-1185
15. Gan W.Q., Man S.F., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 7 (2004 Jul) 574-580
16. Cote C, Pinto-Plata V, Nekach H, Nguyen M, Dordelly L, Celli B. Co-morbidities in COPD: How many and how significant [abstract]. American Thoracic Society International Conference, Toronto, Canada; May 16-21, 2008. p. Poster Board #730.
17. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., and Connett J.E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 4 (2005 Feb 15) 233-239
18. Sin D.D., Wu L., Anderson J.A., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 12 (2005 Dec) 992-997
19. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 8 (2007 Feb 22) 775-789
20. Myers J., Prakash M., Froelicher V., Do D., Partington S., and Atwood J.E. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346 11 (2002 Mar 14) 793-801
21. Oga T., Nishimura K., Tsukino M., Sato S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167 4 (2003 Feb 15) 544-549
22. Pinto-Plata V.M., Cote C., Cabral H., Taylor J., and Celli B.R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 23 1 (2004 Jan) 28-33
23. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 10 (2004 Mar 4) 1005-1012
24. Imfeld S., Bloch K.E., Weder W., and Russi E.W. The BODE index after lung volume reduction surgery correlates with survival. Chest 129 4 (2006 Apr) 873-878
25. Martinez F.J., Han M.K., Andrei A.C., et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 178 5 (2008 Sep 1) 491-499
26. Casanova C., Cote C., de Torres J.P., et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 6 (2005 Mar 15) 591-597
27. Albuquerque A.L., Nery L.E., Villaca D.S., et al. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III. Eur Respir J 28 5 (2006 Nov) 939-944
28. Vassaux C., Torre-Bouscoulet L., Zeineldine S., et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J 32 5 (2008 Nov) 1275-1282
29. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 117 5 Suppl. 2 (2000 May) 398S-401S
30. Wedzicha J.A. Mechanisms of exacerbations. Novartis Found Symp 234 (2001) 84-93 discussion 103
31. Connors Jr. A.F., Dawson N.V., Thomas C., et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med 154 4 Pt 1 (1996 Oct) 959-967
32. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., Salcedo E., Navarro M., and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 11 (2005 Nov) 925-931
33. Soler-Cataluna J.J., Martinez-Garcia M.A., Sanchez L.S., Tordera M.P., and Sanchez P.R. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 103 5 (2009 May) 692-699
34. Barnes P.J., Chowdhury B., Kharitonov S.A., et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 1 (2006 Jul 1) 6-14
35. Barnes N.C., Qiu Y.S., Pavord I.D., et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173 7 (2006 Apr 1) 736-743
36. Spira A., Beane J., Pinto-Plata V., et al. Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol. 31 6 (2004 Dec) 601-610
37. Chen H.Y., Yu S.L., Chen C.H., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356 1 (2007 Jan 4) 11-20
38. Sin D.D., and Man S.F.P. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 3 7 (2006) 624-629
39. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 3 (2007 Feb 1) 250-255
40. CRP as predictor of mortality in COPD. In: DeTorres C.B. (Ed). Comorbidities in COPD (2008 March 10), Jacksonville, FL
41. Hurst J.R., Donaldson G.C., Perera W.R., et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 8 (2006 Oct 15) 867-874
42. Pinto-Plata V., Toso J., Lee K., et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 62 7 (2007 Jul) 595-601